{"preliminary_commentary":{"by_channel":{"x_thread":14,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03977571\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"NORDIC-SUN","nct_id":"NCT03977571","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nordic-sun-nct03977571. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"NORDIC-SUN","arms":[{"description":"Surgery after induction therapy with IO/IO or a TKI/IO-combination, followed by maintenance therapy with nivolumab or a TKI/IO-combination.","label":"Deferred nephrectomy","type":"EXPERIMENTAL"},{"description":"Induction therapy wih IO/IO or a TKI/IO-combination, followed by maintenance therapy with nivolumab or a TKI/IO-combination.","label":"No surgery","type":"ACTIVE_COMPARATOR"}],"collaborators":["Aarhus University Hospital"],"completion_date":{"date":"2031-12-01","type":"ESTIMATED"},"conditions":["Kidney Cancer","Renal Cell Carcinoma Metastatic","Synchronous Neoplasm"],"enrollment":{"count":400,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Cytoreductive nephrectomy","otherNames":[],"type":"PROCEDURE"},{"name":"Tissue sampling","otherNames":[],"type":"OTHER"}],"last_update":"2026-09-23","lead_sponsor":"Niels Fristrup","official_title":"Multicenter Randomized Trial of Deferred Cytoreductive Nephrectomy in Synchronous Metastatic Renal Cell Carcinoma Receiving Checkpoint Inhibitors: a Trial Evaluating the Impact of Surgery or No Surgery. The NORDIC-SUN-Trial","overall_status":"RECRUITING","phases":["NA"],"primary_completion_date":{"date":"2028-12-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Overall survival","timeFrame":"Minimum 3 years follow-up"}],"references":[{"citation":"Flammia RS, Campi R, Bologna E, Bertolo R, Leonardo C, Calabro F, Amparore D, Simone G; Young Academic Urologists (YAU) Renal Cancer Working Group. Cytoreductive nephrectomy in the era of immune-checkpoint inhibitors: back to the future? BJU Int. 2026 May;137(5):763-769. doi: 10.1111/bju.70168. Epub 2026 Feb 11.","pmid":"41673778","type":"DERIVED"},{"citation":"Iisager L, Ahrenfeldt J, Donskov F, Ljungberg B, Bex A, Lund L, Lyskjaer I, Fristrup N. Multicenter randomized trial of deferred cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma receiving checkpoint inhibitors: the NORDIC-SUN-Trial. BMC Cancer. 2024 Feb 24;24(1):260. doi: 10.1186/s12885-024-11987-3.","pmid":"38402173","type":"DERIVED"},{"citation":"Kuusk T, Abu-Ghanem Y, Mumtaz F, Powles T, Bex A. Perioperative therapy in renal cancer in the era of immune checkpoint inhibitor therapy. Curr Opin Urol. 2021 May 1;31(3):262-269. doi: 10.1097/MOU.0000000000000868.","pmid":"33742979","type":"DERIVED"}],"start_date":{"date":"2020-07-06","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Deferred Cytoreductive Nephrectomy in Synchronous Metastatic Renal Cell Carcinoma: The NORDIC-SUN-Trial","url":"https://clinicaltrials.gov/study/NCT03977571"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nordic-sun-nct03977571"}